Released Aug 12, 2011, during market hours
10-Q filed Aug 12, 2011, 43 days after period end · 0001019687-11-002572
Q2 2011 · 10-Q
Revenue$6.07K$6.07K −99.9% vs Q2 2010−99.9% vs Q1 2011
Net Income-$984.00K-$984.00K N/M vs Q2 2010N/M vs Q1 2011
EPS Diluted-$0.02-$0.02 N/M vs Q2 2010N/M vs Q1 2011
Operating Income-$1,053,000N/M
Operating Cash Flowderived-$85,000—
Free Cash Flowderived-$665,000—
Margins · derived
Operating margin-17347.6%−17341.0 pt vs Q2 2010
Net margin-16210.9%−16203.5 pt vs Q2 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2011 | Q2 2010 |
|---|---|---|
| Revenue | $6.07K | $6.19M |
| Net Income | -$984.00K | -$457.00K |
| EPS Diluted | -$0.02 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR